不同药物对新诊断2型糖尿病患者控制血糖的疗效观察

Efficacy of different treatments in newly diagnosed type 2 diabetic patients

目的:观察不同药物对新诊断2型糖尿病患者的疗效。方法:102例新诊断的2型糖尿病患者随机分为艾塞那肽组(34例)、胰岛素组(34例)和二甲双胍组(34例)。三组患者治疗周期均为16周。分别于治疗前、治疗8周及16周测量糖化血红蛋白(HbAlc)、空腹血糖(FPG)、餐后2 h血糖(2h-PG),低血糖发生率、体重变化情况。结果:三组患者经治疗8周和16周时HbAlc、FPG和2h-PG均降低(P<0.05或0.01),并且艾塞那肽组及胰岛素组血糖下降与二甲双胍组相比差别有统计学意义(P<0.05或0.01)。结论:三种药物对新诊断2型糖尿病患者血糖均能控制良好,艾塞那肽注射液及胰岛素的降糖效果优于二甲双胍,艾塞那肽注射液及二甲双胍减重效果优于胰岛素。

Objective ： To observe the efficacy of different oral hypoglycemic drugs in newly diagnosed type 2 diabetic patients. Methods： In a 16 - week study, a total of 102 patients were randomized to three groups ： exenatide（ n = 34）, insulin （ n= 34） and metformiu （ n = 34 ）. HbA1 c, FPG, 2h - PG, hypoglycemia incidence rate and body weight were measured at weeks 0 （ baseline）, 8 and 16. Results： After 8 - week and 16 - week treatment, the levels of HbA1c, FPG,2hPG decreased in all three groups （P 〈 0.05 or 0.01 ）, and the glucose level in exenatide and insulin groups had statistical significance with that in metformin group（P 〈0.05 or 0.01 ）. Conclusion： Three oral hypoglycemic drugs can effectively improve glycaemic control in patients with newly diagnosed type 2 diabetes. Moreover, exenatide and insulin are more effective than metformin. Compared to insulin, exenatide and metformin have a higher incidence of weight loss than insulin